Cough After PCV20 Vaccination
Cough is not listed as a common adverse reaction after PCV20 vaccination in clinical trials or post-licensure surveillance data. The most frequently reported adverse reactions are injection site pain, muscle pain, fatigue, headache, and joint pain 1.
Evidence from Clinical Trials
In the pivotal PCV20 trials among pneumococcal vaccine-naïve adults, the most common adverse reactions were 1:
- Injection site pain: 50-61% (adults 18-59 years), 55% (adults ≥60 years)
- Muscle pain (myalgia): 50-67% (adults 18-59 years), 39% (adults ≥60 years)
- Fatigue: 40-43% (adults 18-59 years), 30% (adults ≥60 years)
- Headache: 32-39% (adults 18-59 years), 22% (adults ≥60 years)
- Joint pain: 13-15% (adults 18-59 years), 13% (adults ≥60 years)
Cough was not identified among the frequently reported adverse reactions in any of the seven clinical trials that included 4,552 PCV20 recipients 1.
Post-Licensure Safety Data
Post-licensure surveillance through VAERS (October 2021–August 2022) reviewed 412 reports related to PCV20 1. Among 274 reports where PCV20 was administered alone, the most common adverse events were 1:
- Injection site erythema (26.6%)
- Injection site swelling (22.6%)
- Injection site pain (22.3%)
Cough was not identified as a disproportionately reported adverse event in the VAERS data mining analysis 1.
A more recent VAERS review (October 2021–December 2023) of 1,976 reports in adults ≥19 years found similar patterns 2:
- Ages 19-64 years: Injection-site reactions (29%), pain (17%), erythema (15%), fever (15%)
- Ages ≥65 years: Injection-site reactions (35%), pain (15%), pain in extremity (14%), erythema (13%)
Cough was not among the commonly reported adverse events in this extended surveillance period 2.
Management Recommendations
If a patient develops cough after PCV20 vaccination:
- Evaluate for alternative causes: Consider concurrent respiratory infections, seasonal allergies, or pre-existing respiratory conditions rather than attributing the symptom to the vaccine 1
- Symptomatic management: Treat cough based on underlying etiology if identified
- Report unexpected events: Healthcare providers should report any suspected adverse events to VAERS by calling 800-822-7967 1
Important Caveats
- Serious adverse events are rare: Across all PCV20 trials, serious adverse events occurred in 1.5% of PCV20 recipients versus 1.8% of controls, with no serious adverse events or deaths considered vaccine-related 1
- Most reactions are mild and self-limited: Local reactions and systemic events typically persist for less than 48 hours and are mild to moderate in severity 1, 2
- Do not delay necessary vaccination: The absence of cough as a documented adverse reaction should not influence vaccination decisions for eligible adults 1